Capital Advisors Ltd’s BridgeBio Pharma BBIO Stock Holding History

Capital Advisors Ltd’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-18	Closed	–	–	1221
2022 Q3	$0	Buy	+18	New	+$187	﹤0.01%	1241
2022 Q2	–	Sell	-91	Closed	-$1K	–	1004
2022 Q1	$1K	Buy	+91	New	+$934	﹤0.01%	676

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Capital Advisors Ltd's BBIO Position: Q4 2022 in Review

Capital Advisors Ltd sold out of BridgeBio Pharma (BBIO) in Q4 2022, closing a stake of 18 shares.

Capital Advisors Ltd first reported a position in BBIO in Q1 2022 and held it in 2 quarters. The position peaked at $1K in Q1 2022. 179 funds tracked by Wall St. Rank hold BBIO as of Q4 2022.

Capital Advisors Ltd reported no remaining BridgeBio Pharma position as of Q4 2022 after selling out during the quarter.
Capital Advisors Ltd sold 18 BridgeBio Pharma shares in Q4 2022.
Capital Advisors Ltd first reported a position in BridgeBio Pharma in Q1 2022 and held it in 2 quarters.
Capital Advisors Ltd's BridgeBio Pharma position peaked at $1K in Q1 2022.
179 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2022.

Based on Capital Advisors Ltd's 13F filing for Q4 2022, filed 7 Feb 2023.